Fluorodeoxyglucose F18

"Fluorodeoxyglucose F18" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)

Descriptor ID	D019788
MeSH Number(s)	D09.254.229.500
Concept/Terms	Fluorodeoxyglucose F18 Fluorodeoxyglucose F18 F18, Fluorodeoxyglucose 18F-FDG Fluorodeoxyglucose F 18 F 18, Fluorodeoxyglucose Fludeoxyglucose F 18 F 18, Fludeoxyglucose Fluorine-18-fluorodeoxyglucose Fluorine 18 fluorodeoxyglucose 18F Fluorodeoxyglucose Fluorodeoxyglucose, 18F 18FDG 2-Fluoro-2-deoxy-D-glucose 2-Fluoro-2-deoxy-D-glucose 2 Fluoro 2 deoxy D glucose 2-Fluoro-2-deoxyglucose 2 Fluoro 2 deoxyglucose

Below are MeSH descriptors whose meaning is more general than "Fluorodeoxyglucose F18".

Chemicals and Drugs [D]
Carbohydrates [D09]
Deoxy Sugars [D09.254]
Deoxyglucose [D09.254.229]
Fluorodeoxyglucose F18 [D09.254.229.500]

Below are MeSH descriptors whose meaning is related to "Fluorodeoxyglucose F18".

Below are MeSH descriptors whose meaning is more specific than "Fluorodeoxyglucose F18".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Fluorodeoxyglucose F18" by people in this website by year, and whether "Fluorodeoxyglucose F18" was a major or minor topic of these publications.

Bar chart showing 124 publications over 29 distinct years, with a maximum of 12 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1997	0	4	4
1998	0	1	1
1999	1	3	4
2000	2	4	6
2001	3	4	7
2002	1	2	3
2003	0	3	3
2004	0	1	1
2005	2	2	4
2006	3	3	6
2007	3	2	5
2008	3	9	12
2009	4	3	7
2010	3	2	5
2011	1	6	7
2012	5	2	7
2013	2	3	5
2014	1	2	3
2015	2	7	9
2016	1	4	5
2017	1	3	4
2018	0	4	4
2019	1	0	1
2020	0	2	2
2021	1	0	1
2022	2	0	2
2023	1	1	2
2024	1	2	3

Below are the most recent publications written about "Fluorodeoxyglucose F18" by people in Profiles.

Ivanidze J, Sharbatdaran A, McCalla A, Brandmaier A, Andreopoulou E, Cristofanilli M, Cigler T, Balogun OD, Magge RS, Liechty B, Karakatsanis NA, Nehmeh SA, Agee MA, Jean J, Osborne JR, Beal K, Schwartz TH, Pannullo SC, Knisely JPS, Ramakrishna R. [18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases. Eur J Radiol. 2024 Dec; 181:111791.

View in: PubMed
Heholt J, Patel R, Vedaei F, Zabrecky G, Wintering N, Monti DA, Wang Z, Newberg AB, Mohamed FB. Simultaneous arterial spin labeling functional MRI and fluorodeoxyglucose PET in mild chronic traumatic brain injury. J Neuroradiol. 2024 Sep; 51(5):101211.

View in: PubMed
Choi W, Jia Y, Kwak J, Werner-Wasik M, Dicker AP, Simone NL, Storozynsky E, Jain V, Vinogradskiy Y. Novel Functional Radiomics for Prediction of Cardiac Positron Emission Tomography Avidity in Lung Cancer Radiotherapy. JCO Clin Cancer Inform. 2024 03; 8:e2300241.

View in: PubMed
Newberg AB, Wintering NA, Hriso C, Vedaei F, Mohamed FB, Gottfried SE, Ross R. Alterations in cerebral glucose metabolism measured by FDG PET in subjects performing a meditation practice based on clitoral stimulation. F1000Res. 2022; 11:1015.

View in: PubMed
Bryan LJ, Casulo C, Allen PB, Smith SE, Savas H, Dillehay GL, Karmali R, Pro B, Kane KL, Bazzi LA, Chmiel JS, Palmer BA, Mehta J, Gordon LI, Winter JN. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial. JAMA Oncol. 2023 05 01; 9(5):683-691.

View in: PubMed
Subramaniam RM, Duan FM, Romanoff J, Yu JQ, Bartel T, Dehdashti F, Intenzo CM, Solnes L, Sicks J, Stack BC, Lowe VJ. 18F-FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracy-Results from Multicenter ACRIN 6685 Clinical Trial. J Nucl Med. 2022 12; 63(12):1887-1890.

View in: PubMed
Chae SY, Park SH, Lee HS, Ahn JH, Kim SB, Jung KH, Kim JE, Ahn SH, Son BH, Lee JW, Ko BS, Kim HJ, Gong G, Oh JS, Park SY, Moon DH. Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer. Sci Rep. 2022 05 12; 12(1):7858.

View in: PubMed
Chugani HT. Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify? J Nucl Med. 2021 Sep 01; 62(9):1301-1306.

View in: PubMed
Kyritsis AP, Markoula S, Alexiou G, Asimakopoulos A, Jabbour P, Fotopoulos A, Sioka C. Diagnosis and treatment of limbic encephalitis in the cancer patient. Future Oncol. 2020 Aug; 16(22):1647-1655.

View in: PubMed
Tripathi SK, Kean R, Bongiorno E, Hooper DC, Jin YY, Wickstrom E, McCue PA, Thakur ML. Targeting VPAC1 Receptors for Imaging Glioblastoma. Mol Imaging Biol. 2020 04; 22(2):293-302.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement